01686nas a2200469   4500000000100000008004100001260001300042653001500055653001000070653001200080653002400092653001000116653001100126653000900137653001700146653001600163653001100179653002500190653000900215653000900224653003200233653002500265653003000290653000900320653001500329653001700344100001800361700001300379700002300392700001500415700001500430700001600445700001700461700001400478700001700492700001500509245006000524300001100584490000700595520060000602022001401202       1994                            d  c1994 Jul10aAdolescent10aAdult10aAnimals10aAntigens, Bacterial10aChild10aFemale10aFoot10aFusidic Acid10aGlycolipids10aHumans10aLeprosy, lepromatous10aMale10aMice10aMicrobial Sensitivity Tests10aMycobacterium leprae10apolymerase chain reaction10aSkin10aSpirometry10aTime Factors1 aFranzblau S G1 aChan G P1 aGarcia-Ignacio B G1 aChavez V E1 aLivelo J B1 aJimenez C L1 aParrilla M L1 aCalvo R F1 aWilliams D L1 aGillis T P00aClinical trial of fusidic acid for lepromatous leprosy.  a1651-40 v383 a<p>Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.</p>  a0066-4804